Navigation Links
Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
Date:10/16/2008

TEMPE, Ariz., Oct. 16 /PRNewswire/ -- A team of researchers from Intrinsic Bioprobes Inc. has reported on a novel quantitative mass spectrometry immunoassay for the detection of bioactive B-type natriuretic peptide (BNP), in an article published online on Oct. 14 in the journal of Circulation: Heart Failure. In collaboration with colleagues from Scios Inc. in Fremont, Christ Hospital in Cincinnati, and Medivation Inc. in San Francisco, the team discovered very low concentration of bioactive BNP in plasma obtained from patients with heart failure, and presented direct structural evidence for several proteolytically degraded forms of BNP in these patients.

"Commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, since they measure both unprocessed, inactive proBNP and mature BNP 1-32," says Eric Niederkofler, Ph.D., the principal investigator from Intrinsic Bioprobes. BNP is synthesized as a 108 amino acid propeptide and proteolytically processed to release an inactive 76 amino acid N-terminal fragment and bioactive mature BNP 1-32 into the bloodstream. "This is the first assay capable of detecting and quantifying BNP 1-32 alone. Furthermore, the assay allowed us to study the molecular complexity of BNP degradation, revealing rapid in vitro degradation of BNP 1-32, and necessitating certain preservation protocol during blood collection and subsequent sample handling," adds Niederkofler.

"This work is going to add greater clarity to how clinicians and researchers approach natriuretic peptides and heart failure," says Dr. Roger Mills, from Ortho McNeil Jannsen Scientific Affairs. "The results may provide an explanation for the 'natriuretic paradox' of increased natriuretic hormone levels with blunted effects in heart failure patients."

Intrinsic Bioprobes Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay (MSIA), a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high throughput analysis of proteins from complex biological matrices, and Bioreactive Mass Spectrometer Probes (BRP), devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high throughput mass spectrometry platform for rapid proteome analysis. For more information about Intrinsic Bioprobes Inc., please visit http://www.intrinsicbio.com.

Contact:

Intrinsic Bioprobes Inc.

Monte Cain, Director of Business Development

Tel.: (480) 804-1778

E-mail: monte@intrinsicbio.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Intrinsic Bioprobes Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
2. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
3. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
4. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
5. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
6. UC Riverside researcher develops novel method to grow human embryonic stem cells
7. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
8. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
9. Tree branching key to efficient flow in nature and novel materials
10. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
11. GEN Reports on Novel Hit-to-Lead Drug Discovery Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):